Abstract
Background
Low serum albumin was found as a predictor of long-term mortality in colorectal cancer (CRC) patients. Our aim was to evaluate the value of the pretreatment albumin/globulin ratio (AGR) to predict the long-term mortality in CRC patients.
Methods
Patients were included if they had comprehensive metabolic panel (CMP) before treatment (surgery or chemotherapy). The albumin/globulin ratio, routinely reported in CMP, is calculated [AGR = Albumin/(Total protein − Albumin)]. Patients were divided into three equal tertiles according to their pretreatment AGR. The primary outcome was cancer-related mortality, which was obtained from our cancer registry database.
Results
A total of 534 consecutive CRC patients had pretreatment CMP. The 1st AGR tertile had a significant higher 4-year mortality compared to the second and third AGR tertiles (42 vs. 19 and 7 %, p < 0.0001 according to Fisher’s exact two-tailed test). In the multivariate model, AGR remained an independent predictor of survival with 75 % decrease in mortality among the highest AGR tertile in comparison to the lowest AGR tertile, p < 0.0001. In the subset of 234 patients with normal serum albumin (albumin of >3.5 g/dl), serum AGR continues to be an independent predictor of cancer-related mortality with an adjusted hazard ratio of the third tertile compared to the first tertile equal to 0.05 (95 % confidence interval 0.01–0.33, p = 0.002).
Conclusion
Low AGR was a strong independent predictor of long-term cancer-specific survival among colorectal cancer patients. Additionally, among the patients with normal albumin (>3.5 g/dl), patients with lower globulins but higher albumin and AGR levels had better survival.
Similar content being viewed by others
References
American Cancer Society (2011) Colorectal cancer facts & figures 2011–2013. American Cancer Society, Atlanta
Betge J, Pollheimer MJ, Lindtner RA et al (2012) Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 118(3):628–638
Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28(2):264–271
Huh JW, Kim HR, Kim YJ (2010) Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer. J Gastrointest Surg 14(7):1074–1080
Swanson RS, Compton CC, Stewart AK, Bland KI (2003) The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10(1):65–71
Wohlke M, Schiffmann L, Prall F (2011) Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up. Histopathology 59(5):857–866
Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M (2011) Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med 2(1):95–101
Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1):149–163
Inoue Y, Iwata T, Okugawa Y et al (2013) Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology 84(2):100–107
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081
McPherson R, Pincus MR (2011) Henry’s clinical diagnosis and management by laboratory methods, 22nd edn. Saunders, Philadelphia
Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6):448–454
McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213
Fearon KC, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T (1998) Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg 227(2):249–254
Andersson C, Lonnroth C, Moldawer LL, Ternell M, Lundholm K (1990) Increased degradation of albumin in cancer is not due to conformational or chemical modifications in the albumin molecule. J Surg Res 49(1):23–29
Lai CC, You JF, Yeh CY et al (2011) Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Color Dis 26(4):473–481
McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Color Dis 22(8):881–886
Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69
Cengiz O, Kocer B, Surmeli S, Santicky MJ, Soran A (2006) Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit 12(6):CR240–CR247
Dixon MR, Haukoos JS, Udani SM et al (2003) Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg 138(9):962–966
Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43(3):163–168
Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K (2007) Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 246(6):1047–1051
Kaysen GA (2001) The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol: JASN 12(7):1549–1557
Kaysen GA (2003) Serum albumin concentration in dialysis patients: why does it remain resistant to therapy? Kidney Int Suppl 87:S92–S98
Sonnenschein C, Soto AM, Michaelson CL (1996) Human serum albumin shares the properties of estrocolyone-I, the inhibitor of the proliferation of estrogen-target cells. J Steroid Biochem Mol Biol 59(2):147–154
Laursen I, Briand P, Lykkesfeldt AE (1990) Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res 10(2A):343–351
Cohen MH, Makuch R, Johnston-Early A et al (1981) Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 65(3–4):187–195
Codina Cazador A, Salva Lacombe JA, Fernandez-Llamazares Rodriguez J, Ruiz Feliu B, Codina Barreras A, Moreno Aguado V (1989) Immunoglobulins and the complement system in colorectal cancer. Rev Esp Enferm Apar Dig 75(2):143–148
Oner F, Savas I, Numanoglu N (2004) Immunoglobulins and complement components in patients with lung cancer. Tuberk Toraks 52(1):19–23
Shimada H, Nabeya Y, Okazumi S et al (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83(4):248–252
Gerhardt T, Milz S, Schepke M et al (2006) C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 12(34):5495–5500
Canna K, McArdle PA, McMillan DC et al (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92(4):651–654
Osman W, Okada Y, Kamatani Y, Kubo M, Matsuda K, Nakamura Y (2012) Association of common variants in TNFRSF13B, TNFSF13, and ANXA3 with serum levels of non-albumin protein and immunoglobulin isotypes in Japanese. PLoS One 7(4):e32683
Al-Joudi FS (2005) Prognostic value of an index for serum globulin compensation in colon and breast cancers. Singap Med J 46(12):710–713
Hong KW, Jin HS, Song D, Kwak HK, Soo Kim S, Kim Y (2013) Genome-wide association study of serum albumin:globulin ratio in Korean populations. J Hum Genet 58(3):174–177
Conflict of interest
The authors report no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Azab, B., Kedia, S., Shah, N. et al. The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer. Int J Colorectal Dis 28, 1629–1636 (2013). https://doi.org/10.1007/s00384-013-1748-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-013-1748-z